Skip to main content
Caplight Logo









FEMSelect

FEMSelect

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.femselect.com/

Last Round

Series B

Extension

May 13, 2025

Total Funding Raised

$14.3M

Company Overview

FEMSelect is a medical technology company that develops minimally invasive surgical systems for the treatment of pelvic organ prolapse.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

pelvic organ prolapsesurgical meshminimally invasive surgeryurogynecologypelvic floor reconstructionmedical devicesurgical systemwomen's healthPOP repairmesh-free surgerysurgical kitspelvic floor disorders

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FEMSelect Comparables

Compare FEMSelect with similar companies based on industry and business-model similarity.

FEMSelect comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Escala Medical
92%
Neomedic International
82%
Caldera Medical
80%

FEMSelect Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 13, 2025
Series BOct 19, 2022
Series AJan 24, 2018
SeedDec 1, 2012

Key People

Founding team and executive leadership

Deborah Garner

President CEO

Executive Team

Sasha Schrode

Chief Executive Officer

Executive Team

FEMSelect Investors

Notable investors and investment history

FEMSelect investors
InvestorRounds
Nordwand CapitalSeries B Extension
TransPacific Venture PartnersSeries B
Robin Hood VenturesSeries B Extension, Series B
Keiretsu CapitalSeries B
MEDA AngelsSeries B
Keiretsu Forum Mid-AtlanticSeries B
TriventuresSeries B Extension, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 41% MoM.

  • Jun 6, 2025

    Grew 25% QoQ from 12 to 15 employees.

FEMSelect Filings

Explore SEC and related filing metadata, where available.

FEMSelect filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FEMSelect's valuation, stock price, and market status.

Is FEMSelect a public or private company?

FEMSelect is a private company.

What is the current stock price of FEMSelect?

FEMSelect is a private company with no public stock price. No recent secondary market data is available.

How much is FEMSelect worth (valuation)?

Valuation information for FEMSelect is not publicly available.

Can I buy FEMSelect stock?

FEMSelect shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was FEMSelect's last funding round?

FEMSelect's most recent funding round was Series B Extension on May 13, 2025.

Who are the main investors in FEMSelect?

Key investors in FEMSelect include Triventures, New Age Ventures, RAD BioMed.

Will FEMSelect IPO soon?

No public IPO plans have been announced for FEMSelect.

How can I track FEMSelect secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor FEMSelect's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range11
Year Founded2012
Last FundingMay 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?